Terms: = Breast cancer AND ATR, Q13535, 545, ENSG00000175054, MEC1, SCKL, SCKL1, FRP1 AND Treatment
196 results:
1. The atr inhibition by Elimusertib enhances the radiosensitivity of MDA-MB-231 triple negative breast cancer in vitro.
Guney Eskiler G; Halis H; Hamarat KF; Derlioglu RR; Ugurlu BT; Haciefendi A
Int J Radiat Biol; 2024; 100(5):715-723. PubMed ID: 38421209
[TBL] [Abstract] [Full Text] [Related]
2. Blocking LBH expression causes replication stress and sensitizes triple-negative breast cancer cells to atr inhibitor treatment.
Garikapati K; Young IC; Hong S; Rai P; Jain C; Briegel KJ
Oncogene; 2024 Mar; 43(12):851-865. PubMed ID: 38297083
[TBL] [Abstract] [Full Text] [Related]
3. Construction and validation of a prognostic nutritional index-based nomogram for predicting pathological complete response in breast cancer: a two-center study of 1,170 patients.
Qu F; Luo Y; Peng Y; Yu H; Sun L; Liu S; Zeng X
Front Immunol; 2023; 14():1335546. PubMed ID: 38274836
[TBL] [Abstract] [Full Text] [Related]
4. Targeted delivery and apoptosis induction of CDK-4/6 inhibitor loaded folic acid decorated lipid-polymer hybrid nanoparticles in breast cancer cells.
Rajana N; Sandeep Chary P; Bhavana V; Deshmukh R; Dukka K; Sharma A; Kumar Mehra N
Int J Pharm; 2024 Feb; 651():123787. PubMed ID: 38184023
[TBL] [Abstract] [Full Text] [Related]
5. CHARIOT: a phase I study of berzosertib with chemoradiotherapy in oesophageal and other solid cancers using time to event continual reassessment method.
Javed SR; Lord S; El Badri S; Harman R; Holmes J; Kamzi F; Maughan T; McIntosh D; Mukherjee S; Ooms A; Radhakrishna G; Shaw P; Hawkins MA
Br J Cancer; 2024 Feb; 130(3):467-475. PubMed ID: 38129525
[TBL] [Abstract] [Full Text] [Related]
6. The impact of metabolic syndrome in breast reconstruction decision-making and postoperative outcomes: A nationwide analysis.
Escobar-Domingo MJ; Bustos VP; Kim EJ; Campbell T; Fanning JE; Foppiani JA; Merle C; Lin SJ; Lee BT
J Plast Reconstr Aesthet Surg; 2024 Feb; 89():21-29. PubMed ID: 38128370
[TBL] [Abstract] [Full Text] [Related]
7. Design, development, and evaluation of CDK-4/6 inhibitor loaded 4-carboxy phenyl boronic acid conjugated pH-sensitive chitosan lecithin nanoparticles in the management of breast cancer.
Pooja YS; Rajana N; Yadav R; Naraharisetti LT; Godugu C; Mehra NK
Int J Biol Macromol; 2024 Feb; 258(Pt 1):128821. PubMed ID: 38110163
[TBL] [Abstract] [Full Text] [Related]
8. Development of a Practical Nomogram for Personalized Anemia Management in Patients Treated with Ataxia Telangiectasia and Rad3-related Inhibitor Camonsertib.
Rosen E; Yap TA; Lee EK; Højgaard M; Mettu NB; Lheureux S; Carneiro BA; Plummer R; Fretland AJ; Ulanet D; Xu Y; McDougall R; Koehler M; Fontana E
Clin Cancer Res; 2024 Feb; 30(4):687-694. PubMed ID: 38078898
[TBL] [Abstract] [Full Text] [Related]
9. Mechanisms of PARP Inhibitor Resistance.
O'Connor MJ; Forment JV
Cancer Treat Res; 2023; 186():25-42. PubMed ID: 37978129
[TBL] [Abstract] [Full Text] [Related]
10. Abrogation of atr function preferentially augments cisplatin-induced cytotoxicity in PTEN-deficient breast cancer cells.
Zhao JL; Yang J; Li K; Chen Y; Tang M; Zhu HL; Nie CL; Yuan Z; Zhao XY
Chem Biol Interact; 2023 Nov; 385():110740. PubMed ID: 37802411
[TBL] [Abstract] [Full Text] [Related]
11. Olaparib and Ceralasertib (AZD6738) in Patients with Triple-Negative Advanced breast cancer: Results from Cohort E of the plasmaMATCH Trial (CRUK/15/010).
Ring A; Kilburn LS; Pearson A; Moretti L; Afshari-Mehr A; Wardley AM; Gurel B; Macpherson IR; Riisnaes R; Baird RD; Martin S; Roylance R; Johnson H; Ferreira A; Winter MC; Dunne K; Copson E; Hickish T; Burcombe R; Randle K; Serra V; Llop-Guevara A; Bliss JM; Turner NC
Clin Cancer Res; 2023 Dec; 29(23):4751-4759. PubMed ID: 37773077
[TBL] [Abstract] [Full Text] [Related]
12. FDA Approval Summary: Ribociclib Indicated for Male Patients with Hormone Receptor-Positive, HER2-Negative Advanced or Metastatic breast cancer.
Gao JJ; Osgood CL; Feng Z; Bloomquist EW; Tang S; Chang CJG; Ricks TK; Hou SC; Pierce WF; Rivera DR; Pazdur R; Kluetz PG; Amiri-Kordestani L
Clin Cancer Res; 2023 Dec; 29(24):5008-5011. PubMed ID: 37594723
[TBL] [Abstract] [Full Text] [Related]
13. Analysis of Quinolinequinone Analogs with Promising Cytotoxic Activity against breast cancer.
Yilmaz Goler AM; Tarbin Jannuzzi A; Biswas A; Mondal S; Basavanakatti VN; Jayaprakash Venkatesan R; Yıldırım H; Yıldız M; Çelik Onar H; Bayrak N; Jayaprakash V; TuYuN AF
Chem Biodivers; 2023 Sep; 20(9):e202300848. PubMed ID: 37590495
[TBL] [Abstract] [Full Text] [Related]
14. Enhanced efficacy of combined fluzoparib and chidamide targeting in natural killer/T-cell lymphoma.
Gong C; Wu J; Song W; Li H; Shi C; Gao Y; Shi Z; Li Z; Zhang M
Ann Hematol; 2023 Oct; 102(10):2845-2855. PubMed ID: 37500898
[TBL] [Abstract] [Full Text] [Related]
15. Fiber optic probe-based atr-FTIR spectroscopy for rapid breast cancer detection: A pilot study.
Zhang S; Vasudevan S; Tan SPH; Olivo M
J Biophotonics; 2023 Nov; 16(11):e202300199. PubMed ID: 37496212
[TBL] [Abstract] [Full Text] [Related]
16. Molecular portraits of cell cycle checkpoint kinases in cancer evolution, progression, and treatment responsiveness.
Oropeza E; Seker S; Carrel S; Mazumder A; Lozano D; Jimenez A; VandenHeuvel SN; Noltensmeyer DA; Punturi NB; Lei JT; Lim B; Waltz SE; Raghavan SA; Bainbridge MN; Haricharan S
Sci Adv; 2023 Jun; 9(26):eadf2860. PubMed ID: 37390209
[TBL] [Abstract] [Full Text] [Related]
17. Analysis of breast cancer Family History, Estrogen Receptor Status, and breast cancer Outcomes in Sweden.
Zhang Y; Wang QL; Zeng E; He W; Czene K
JAMA Netw Open; 2023 Jun; 6(6):e2318053. PubMed ID: 37310740
[TBL] [Abstract] [Full Text] [Related]
18. Immediate breast Reconstruction After Neoadjuvant Chemotherapy: Factors Associated With Surgical Selection and Complications.
Chi W; Zhang Q; Li L; Chen M; Xiu B; Yang B; Wu J
Ann Plast Surg; 2023 Jul; 91(1):48-54. PubMed ID: 37216212
[TBL] [Abstract] [Full Text] [Related]
19. New perspective on DNA response pathway (DDR) in glioblastoma, focus on classic biomarkers and emerging roles of ncRNAs.
Pirlog BO; Ilut S; Pirlog R; Chiroi P; Nutu A; Radutiu DI; Cuc GD; Berindan-Neagoe I; Nabavi SF; Filosa R; Nabavi SM
Expert Rev Mol Med; 2023 May; 25():e18. PubMed ID: 37154101
[TBL] [Abstract] [Full Text] [Related]
20. Selective Inhibition of ATM-dependent Double-strand Break Repair and Checkpoint Control Synergistically Enhances the Efficacy of atr Inhibitors.
Turchick A; Zimmermann A; Chiu LY; Dahmen H; Elenbaas B; Zenke FT; Blaukat A; Vassilev LT
Mol Cancer Ther; 2023 Jul; 22(7):859-872. PubMed ID: 37079339
[TBL] [Abstract] [Full Text] [Related]
[Next]
